Reuters (7/8, Kelland) reports that according to a study published in the journal Alzheimer’s & Dementia, researchers in the UK have completed identification of 10 blood proteins predictive of the onset of Alzheimer’s disease in people who have mild cognitive impairment (MCI) with a little less than 90% accuracy.
Reuters notes that pharmaceutical companies such as Eli Lilly, Merck, and Johnson & Johnson are using different approaches to develop treatments to stop progression of the disease. However, over the past decade and a half more than 100 experimental drugs have failed in trial, which one of the authors of the study said could be attributed to conducting drug trials at too late a stage.
Related Links:
— “Study paves the way for a blood test to predict Alzheimer’s,” Kate Kelland, Reuters, July 7, 2014.